Loading...
Market
Leading biotech investor in APOE4 research by 2024
5
Resolution / Starting Odds
Biogen • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Corporate press releases and financial news
Story
APOE4 Gene Variant Linked to 100% Chance of Alzheimer's, Study Finds
May 6, 2024, 06:45 PM
Recent studies have identified a distinct genetic form of Alzheimer's disease linked to the APOE4 gene variant. Researchers have found that individuals with two copies of the APOE4 gene, known as homozygotes, exhibit nearly a 100% chance of developing Alzheimer's and show significant biological markers such as abnormal amyloid levels and biomarkers in cerebrospinal fluid. This discovery marks a significant shift in understanding the gene's role from a risk factor to a direct cause, potentially leading to earlier diagnoses and more targeted treatments.
View original story
Similar markets
Increased investment in existing Alzheimer's drugs • 33%
Development of new APOE4-specific treatments • 33%
No significant change in investment • 33%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Novartis • 25%
Treatment introduced by end of 2025 • 33%
Treatment delayed beyond 2025 • 33%
No treatment introduced • 34%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Novartis • 25%
